Answers are grounded in this paper and cite their sources.
Objective This study explored the active components and mechanisms of Cistanche deserticola Ma (CH) in treating acute kidney injury (AKI) using network pharmacology, GEO data, and experimental validation. Methods Active compounds and targets of CH were identified from TCMSP, SwissTargetPrediction, and Herb databases. AKI-related genes were sourced from GeneCards, OMIM, and GEO. A protein-protein interaction (PPI) network of overlapping targets was constructed via STRING, with key nodes ranked using CytoNCA. GO/KEGG enrichment was performed in R, and a target-pathway network was built in Cytoscape. Molecular docking was conducted with Discovery Studio and visualized in Pymol. In vitro assays, including MTT, flow cytometry, and Western blotting, validated quercetin’s effects on LPS-induced HK-2 cell injury. Results Five active CH compounds and 397 potential targets were identified, with 221 overlapping AKI targets. Core targets included TP53, IL-6, AKT1, EGFR, TNF, and SRC. Enrichment analysis highlighted the PI3K/AKT pathway, apoptotic regulation, and xenobiotic response. Quercetin showed strong binding to core targets and reduced apoptosis via PI3K/AKT inhibition in vitro. Conclusion CH may protect against AKI through PI3K/AKT pathway modulation, supporting its therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: